Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2021-02-12 5:13 pm Purchase |
2020-12-31 | 13G | Xenon Pharmaceuticals Inc. XENE |
ORBIMED ADVISORS LLC | 1,711,305 4.890% |
1,076,493 (+169.58%) |
Filing History |
| 2021-02-12 5:12 pm Purchase |
2020-12-31 | 13G | VistaGen Therapeutics, Inc. VTGN |
ORBIMED ADVISORS LLC | 325,960 6.900% |
325,960 (New Position) |
Filing History |
| 2021-02-12 5:10 pm Purchase |
2020-12-31 | 13G | Theravance Biopharma, Inc. TBPH |
ORBIMED ADVISORS LLC | 5,544,212 8.670% |
5,544,212 (New Position) |
Filing History |
| 2021-02-12 5:08 pm Purchase |
2020-12-31 | 13G | Strongbridge Biopharma plc SBBP |
ORBIMED ADVISORS LLC | 2,986,869 4.440% |
2,986,869 (New Position) |
Filing History |
| 2021-02-12 5:07 pm Sale |
2020-12-31 | 13G | Prothena Corporation plc PRTA |
ORBIMED ADVISORS LLC | 1,485,458 3.720% |
-802,981 (-35.09%) |
Filing History |
| 2021-02-12 5:05 pm Purchase |
2020-12-31 | 13G | Otonomy, Inc. OTIC |
ORBIMED ADVISORS LLC | 2,480,800 5.140% |
1,083,233 (+77.51%) |
Filing History |
| 2021-02-12 5:04 pm Sale |
2020-12-31 | 13G | OBSEVA SA COM OBSVF |
ORBIMED ADVISORS LLC | 0 0.000% |
-2,605,531 (Position Closed) |
Filing History |
| 2021-02-12 5:00 pm Purchase |
2020-12-31 | 13G | Mereo BioPharma Group plc MREO |
ORBIMED ADVISORS LLC | 4,518,356 6.660% |
4,518,356 (New Position) |
Filing History |
| 2021-02-12 4:59 pm Purchase |
2020-12-31 | 13G | MeiraGTx Holdings plc MGTX |
ORBIMED ADVISORS LLC | 3,969,425 9.140% |
520,605 (+15.10%) |
Filing History |
| 2021-02-12 4:57 pm Purchase |
2020-12-31 | 13G | Larimar Therapeutics, Inc. LRMR |
ORBIMED ADVISORS LLC | 732,323 4.770% |
732,323 (New Position) |
Filing History |
| 2021-02-12 4:55 pm Sale |
2020-12-31 | 13G | Krystal Biotech, Inc. KRYS |
ORBIMED ADVISORS LLC | 0 0.000% |
-933,508 (Position Closed) |
Filing History |
| 2021-02-12 4:53 pm Purchase |
2020-12-31 | 13G | Kala Pharmaceuticals, Inc. KALA |
ORBIMED ADVISORS LLC | 188,568 8.410% |
50,654 (+36.73%) |
Filing History |
| 2021-02-12 4:52 pm Sale |
2020-12-31 | 13G | Inspire Medical Systems, Inc. INSP |
ORBIMED ADVISORS LLC | 0 0.000% |
-1,347,000 (Position Closed) |
Filing History |
| 2021-02-12 4:49 pm Sale |
2020-12-31 | 13G | Harpoon Therapeutics, Inc. HARP |
ORBIMED ADVISORS LLC | 102,070 4.020% |
-34,000 (-24.99%) |
Filing History |
| 2021-02-12 4:48 pm Purchase |
2020-12-31 | 13G | Forte Biosciences, Inc. FBRX |
ORBIMED ADVISORS LLC | 25,431 4.740% |
25,431 (New Position) |
Filing History |
| 2021-02-12 4:46 pm Purchase |
2020-12-31 | 13G | Standard BioTools Inc. LAB |
ORBIMED ADVISORS LLC | 3,499,246 4.720% |
3,499,246 (New Position) |
Filing History |
| 2021-02-12 4:44 pm Purchase |
2020-12-31 | 13G | Crinetics Pharmaceuticals, Inc. CRNX |
ORBIMED ADVISORS LLC | 2,753,567 8.360% |
714,285 (+35.03%) |
Filing History |
| 2021-02-12 4:41 pm Purchase |
2020-12-31 | 13G | Applied Therapeutics, Inc. APLT |
ORBIMED ADVISORS LLC | 1,666,825 7.410% |
817,571 (+96.27%) |
Filing History |
| 2021-02-12 4:39 pm Purchase |
2020-12-31 | 13G | Aeglea BioTherapeutics, Inc. AGLE |
ORBIMED ADVISORS LLC | 200,621 10.250% |
86,000 (+75.03%) |
Filing History |
| 2021-02-12 4:37 pm Purchase |
2020-12-31 | 13G | Adverum Biotechnologies, Inc. ADVM |
ORBIMED ADVISORS LLC | 484,525 4.970% |
90,116 (+22.85%) |
Filing History |